TABL~ I

Antigen Presentation by I-J + APC and TsF2 are. Required to Activate Ts3
Percent specific release * 3 × 10 v APC from the spleen of (CA)F~ mice were treated with rabbit C' alone or monoclonal anti I-J k (a gift ofC. Wa[tenbaugh) plus C'. These cells wece used to prime (CA)F~ recipients. :~ TsF~ was administered on days 4 and 5 after priming in a total dose of 6 × i0 7 ceil equivalents.
§ ABA-specific cytotoxicity was assayed on Con A (CA)F~ blast cells that were coupled with ABA or left uncoupled in a standard 4-h mCr release assay after restimulation of the primed T cells with ABA-coupled (CA)F~ cells. Targets were Con A-induced (CA)F~ blast cells that were coupled with ABA or left uncoupled arsanilic acid, and injected as described previously (8) .
Immunization of Animals. Mice were immunized subcutaneously with 1-3 × 10 7 ABA-coupled spleen cells. This procedure has been described elsewhere (8) .
Cytotoxic T Lymphocyte (CTL) Assay and Delayed-type Hypersensitivity (DTH). CTL and DTH
assays have been described elsewhere (8, 9) . Briefly, mice were challenged in the footpad with 30 ~1 10 raM-active ABA solution 5 d after immunization. 24 h later, DTH was measured by an investigator unfamiliar with the experimental groups. 0-1 d later, 7 × 10 s responders were cultured with 6 × 106 ABA-coupled x-irradiated (1,500 rad) spleen cells in 2 ml for 5 d. CTL responses were then measured by 51Cr-release assay against ABA-coupled concanavalin A (Con A) blast cells in standard 4-h assay.
Induction and Administration of Second Order Suppressor Factor (TsFz)
. Naive A/J mice received 1.5 × 108 cell equivalents over 5 d of conventional or monoclonal TsF1. TsF2 was prepared from spleen cell freeze-thaw lysates from these mice as described previously (7) . Mice receiving TsF2 were injected with 3 X 10 7 cell equivalents/day on days 4 and 5.
Cyclophosphamide Treatment. Mice receiving cyclophosphamide (Cytotoxan; Mead Johnson & Co., Evansville, IN) were injected intraperitoneally with 20 mg/kg (as noted in text) 2 d before they were killed. Spleen cells were subsequently ABA coupled and injected subcutaneously into two separate dorsal sites as described previously (8) .
Results and Discussion
To generate ABA-specific Tsa effector cells, I-J-restricted presentation of hapten is required (7) . To Characterize the cell (or cells) responsible for this restriction, we treated ABA-coupled APC with monoclonal anti-I-J antibody and C' before immunization. This treatment removed APC required for Ts3 but not for CTL induction (Table I) or for DTH priming (data not shown). It 'should be noted that the same monoclonal antibody has been used to lyse an I-J + APC in another experimental system. 1 Because there is no representation of ABA in the immunized animal (see Table II , ref. 7), we were confident that these immunizing cells were the only source of ABA presentation for Ts3 induction in the recipient mice.
To characterize the expression of I-A encoded determinants on the I-J + APC, we adopted a slightly different protocol. Immunization with monoclonal anti-I-A k + C'-treated ABA-coupled spleen cells fails to prime for anti-ABA DTH or CTL responses (Table II and Table III (GA)Ft were immunized with either 2 × 10 7 ABA-A/J subcutaneously 2 X 10 7 ABA/BALB/c subcutaneously, or both (in separate dorsal sites). In some groups A/J cells were treated with monoclonal anti-I-A k (10,2,16) and G' before ABA coupling, A/J TsF2 was adminhtered on days 4 and 5 after priming in a total dose of 6 X 10 7 cell equivalents, measure suppression. However, we have recently shown that F1 mice immunized with P1 ABA-coupled spleen cells are suppressed by P1 but not P2 TsFz (7) . Exploiting this, we simultaneously immunized CAF1 mice with both anti-I-A k + G'-treated A/J ABAcoupled spleen ceils and normal BALB/c ABA-coupled spleen cells (Table II) . In this way the BALB/c-ABA cells prime for CTL and DTH responses in the CAFx mouse, while the A/J-ABA cells prime the pre-Ts3, which can then be fully activated only by A/J TsF2 (7). As shown in Table II (Table III) . Thus the critical A/J cell needed to effect suppression in concert with A/J TsF2 may be I-A k negative. Although distinct from the I-A + APC in its expression of class II antigens, the I-J + APC is similar in its resistance to 1500 rad of x radiation (10) ( Table III) .
TAaLE III
1-J + APC is I-A-and x-Ray (1,500 rad) Resistant
Because of the well-established cyclophosphamide sensitivity of the suppressor cell pathway (11), we investigated whether mice pretreated with low doses of cyclophosphamide were deficient in this I-J + APC. We found that normal mice immunized with ABA-coupled spleen ceils obtained from eyclophosphamide pretreated donors Table IVA were normalized and pooled from two independent experiments; each group contained a total of eight animals. Significance was determined using the Student's t test. * Cyclophosphamide. :~ Not significant.
(20 mg/kg on day 2) were primed for normal CTL and DTH responses to ABA (Table IV) . Thus the cell involved in the presentation of antigen for activation of Tsa appears to be sensitive to cyclophosphamide. This deficiency of I-J APC function in cyclophosphamide-pretreated animals might also be explained by a cyclophosphamide-sensitive event required for expression of I-J determinants. Finally, the presentation of antigen in a manner that is resistant to suppression is similar to the phenomenon reported by Britz et al. (12) .
The data presented here supports the work of Nakamura et al. (13) who found that an I-J + I-A-adherent cell was required for in vitro induction of Ts effector cells. There is also evidence that a special set of APC is required to trigger mixed leukocyte response suppressor activity (Susan Rich, personal communication). Further, it appears likely that I-J-restricted events in other Ts pathways (4, 14) may be due to I-Jassociated antigen presentation. Elimination of the I-J + APC may explain why free antigen, usually not immunogenic when injected intravenously, can immunize mice pretreated with cyclophosphamide (15) . Collectively, these experiments indicate that antigen can be processed by two distinct APC for activation of either suppressor or immune cells. Selective manipulation of these APC subsets may permit modulation of immunity in a number of pathological processes (16) (17) (18) . 
